Suheung Co., Ltd. (KRX:008490)
20,400
+300 (1.49%)
At close: Oct 2, 2026
Suheung Revenue
Suheung had revenue of 212.90B KRW in the quarter ending June 30, 2026, with 12.04% growth. This brings the company's revenue in the last twelve months to 765.90B, up 11.64% year-over-year. In the year 2025, Suheung had annual revenue of 722.31B with 10.57% growth.
Revenue (ttm)
765.90B
Revenue Growth
+11.64%
P/S Ratio
0.30
Revenue / Employee
988.26M
Employees
775
Market Cap
227.18B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 722.31B | 69.04B | 10.57% |
| Dec 31, 2024 | 653.26B | 58.70B | 9.87% |
| Dec 31, 2023 | 594.57B | -40.40B | -6.36% |
| Dec 31, 2022 | 634.97B | 38.23B | 6.41% |
| Dec 31, 2021 | 596.73B | 43.72B | 7.91% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Huons | 607.75B |
| Samjin Pharmaceuticals | 274.03B |
| Whan In Pharm | 273.47B |
| Korea United Pharm | 161.44B |
| Yungjin Pharm. | 158.79B |
| REYON Pharmaceutical | 143.37B |
| Humedix | 110.99B |
| Hyundai Pharmaceutical | 108.14B |